Essential Thrombocythemia research hub
4 indexed studies · 1 currently recruiting
- recruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
United States · Argentina · Australia - active not recruitingPHASE2
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
This study is testing a new medicine called P1101 for adults with Essential Thrombocythaemia (ET). We want to see if it's safe, works well, and helps manage the condition. P1101 aims to offer a better way to control blood counts and potentially change how ET progresses.
United States · Canada - active not recruitingPHASE3
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
This study is testing a new medicine called Ropeginterferon Alfa-2b for a blood condition known as Essential Thrombocythemia (ET). It compares this new medicine with an existing one, Anagrelide, to see which is safer and works better for patients who haven't responded well to another treatment, Hydroxyurea.
United States · Canada · China